CTE - Cardiotech Intl. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CTE - Cardiotech Intl.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bvortex who started this subject	7/12/2000 4:42:06 PM
From: bvortex	of 6

CTE Announced the end of Trials for New Vasculink Product - Their new generation of Vasculink graft will be submitted for CE approval (Europe's equivalent to FDA Approval). This new generation of graft now has much greater clot prevention due to the addition of heparin bonding to the inside of the polymer graft. This prevention has lasted for upto 3 weeks after insertion, instead of just hours with most other graft materials during surgery. This improvement will be added to CTE other small bore and cardio-based graft products that under trial currently. If anyone has a medical opinion of this new technology, please let me know. Thanks. Bill

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next